Chemical mediators and the resolution of airway inflammation

Allergology International

Volumn 57, Issue 4, 2008, Pages 299-305

  Carlo, Troy ^a   Levy, Bruce D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Airway inflammation; Asthma; Fish; Immune response; Lipid mediators

Indexed keywords

ANTIASTHMATIC AGENT; CD59 ANTIGEN; FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LIPOXIN; LIPOXIN A; LIPOXIN DERIVATIVE; PRESQUALENE DIPHOSPHATE; PRESQUALENE DIPHOSPHATE DERIVATIVE; PROTECTIN D1 DERIVATIVE; PYROPHOSPHATE; RESOLVIN; RESOLVIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOSYNTHESIS; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR;

EID: 59549100673     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-RAI-0018     Document Type: Review

References (70)

1. Busse W, Holgate S. Asthma and Rhinitis. Boston: Blackwell Scientific, 1995.
2. Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma. 2003, Available from: http://www.ginasthma.com.
3. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-6.
4. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984;81:5335-9.
5. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61.
6. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995;92: 9475-9.
7. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994;180:253-60.
8. Bonnans C, Fukunaga K, Levy MA, Levy BD. Lipoxin A (4)regulates bronchial epithelial cell responses to acid injury. [see comment]. Am J Pathol 2006;168:1064-72.
9. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin(IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 1998;187:1285-1294.
10. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 1997;272:6972-8.
11. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000; 164:2660-6.
12. Levy BD, De Sanctis GT, Devchand PR et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).[see comment]. Nat Med 2002;8:1018-23.
13. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 2006;107: 2123-30.
14. Perretti M, Chiang N, La M et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 2002;8:1296-302.
15. Goulding NJ, Godolphin JL, Sampson MB, Maddison PJ, Flower RJ. Hydrocortisone induces lipocortin 1 production by peripheral blood mononuclear cells in vivo in man. Biochem Soc Trans 1990; 18:306-7.
16. Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4)receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001;158:3-9.
17. Schaldach CM, Riby J, Bjeldanes LF. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999;38: 7594-600.
18. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002; 68-69:433-55.
19. Celik GE, Erkekol FO, Misirligil Z, Melli M. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 2007;37:1494-501.
20. Vachier I, Bonnans C, Chavis C et al. Severe asthma is associated with a loss of LX4, an endogenous antiinflammatory compound. J Allergy Clin Immunol 2005; 115:55-60.
21. Levy BD, Bonnans C, Silverman ES et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005; 172:824-30.
22. Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993;92:75-82.
23. Levy BD, Fokin VV, Clark JM, Wakelam MJ, Petasis NA, Serhan CN. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J 1999;13: 903-11.
24. Serhan CN, Maddox JF, Petasis NA et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34: 14609-15.
25. Gewirtz AT, Fokin VV, Petasis NA, Serhan CN, Madara JL. LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. Am J Physiol 1999; 276 (Pt 1):C988-94.
26. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 1996;183:137-46.
27. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate non-phlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000;164: 1663-7.
28. Canny G, Levy O, Furuta GT et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia.[see comment]. Proc Natl Acad Sci U S A 2002;99:3902-7.
29. Levy BD, Petasis NA, Serhan CN. Polyisoprenyl phosphates in intracellular signalling. Nature 1997;389:985-90.
30. Levy BD, Serhan CN. Polyisoprenyl phosphate signaling: topography in human neutrophils. Biochem Biophys Res Commun 2000; 275:739-45.
31. Hawkins PT, Davidson K, Stephens LR. The role of PI3Ks in the regulation of the neutrophil NADPH oxidase. Biochem Soc Symp 2007; 74:59-67.
32. Gomez-Cambronero J, Keire P. Phospholipase D: a novel major player in signal transduction. Cell Signal 1998;10: 387-97.
33. Bonnans C, Fukunaga K, Keledjian R, Petasis NA, Levy BD. Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury. J Exp Med 2006; 203:857-63.
34. Levy BD, Hickey L, Morris AJ et al. Novel polyisoprenyl phosphates block phospholipase D and human neutrophil activation in vitro and murine peritoneal inflammation in vivo. Br J Pharmacol 2005; 146:344-51.
35. Fukunaga K, Arita M, Takahashi M, Morris AJ, Pfeffer M, Levy BD. Identification and functional characterization of a presqualene diphosphate phosphatase. J Biol Chem 2006;281:9490-7.
36. Sigal YJ, McDermott MI, Morris AJ. Integral membrane lipid phosphatases/ phosphotransferases: common structure and diverse functions. Biochem J 2005;387 (Pt 2): 281-93.
37. Olsen JV, Blagoev B, Gnad F et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127:635-48.
38. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172: 2903-8.
39. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-204.
40. Serhan CN, Hong S, Gronert K et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-37.
41. Tjonahen E, Oh SF, Siegelman J et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis.[see comment]. Chem Biol 2006; 13:1193-202.
42. Arita M, Bianchini F, Aliberti J et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201:713-22.
43. Wittamer V, Franssen JD, Vulcano M et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85.
44. Cash JL, Hart R, Russ A et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008; 205:767-75.
45. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007;178:3912-7.
46. Toda A, Yokomizo T, Shimizu T. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat 2002;68-69:575-85.
47. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278:14677-87.
48. Serhan CN, Gotlinger K, Hong S et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. [erratum appears in J Immunol 2006;176: 3843]. J Immunol 2006;176:1848-1859.
49. Marcheselli VL, Hong S, Lukiw WJ et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. [erratum appears in J Biol Chem 2003;278:51974]. J Biol Chem 2003;278:43807-17.
50. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447:869-74.
51. Surette ME, Stull D, Lindemann J. The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients. Curr Med Res Opin 2008;24:559-67.
52. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury.[see comment][erratum appears in Crit Care Med 2006;34:1861]. Crit Care Med 2006;34:1033-8.
53. Gadek JE, DeMichele SJ, Karlstad MD et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group.[see comment]. Crit Care Med 1999;27:1409-20.
54. Duffield JS, Hong S, Vaidya VS et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006; 177:5902-11.
55. Sun YP, Oh SF, Uddin J et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 2007;282:9323-34.
56. Aoki H, Hisada T, Ishizuka T et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008;367:509-515.
57. Haworth O, Zhu G, Cerandas M, Serhan CN, Levy BD. Resolvin E1 Regulates Allergic Airway Inflammation. Toronto: ATS International Conference, 2008.
58. Levy BD, Kohli P, Gotlinger K et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178:496-502.
59. Chu HW, Balzar S, Westcott JY et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. [see comment]. Clin Exp Allergy 2002;32:1558-65.
60. Christie PE, Spur BW, Lee TH. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992; 145:1281-4.
61. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006;5:91-106.
62. O'Sullivan TP, Vallin KS, Shah ST et al. Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J Med Chem 2007;50:5894-902.
63. Levy BD, Lukacs NW, Berlin AA et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21:3877-84.
64. Bandeira-Melo C, Bozza PT, Diaz BL et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000; 164:2267-71.
65. Soyombo O, Spur BW, Lee TH. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy 1994;49:230-4.
66. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol 2002;3:76-82.
67. Arita M, Yoshida M, Hong S et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102:7671-6.
68. Hasturk H, Kantarci A, Ohira T et al. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J 2006;20:401-3.
69. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 2002;99:13266-71.
70. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002;165:1531-5.